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EffiCiEnCy Of REhabilitatiOn PROgRams fOR PatiEnts aftER tRaumatiC 
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Objectives: The objective of the present study was to assess efficiency of rehabili-
tation programs for patients after traumatic brain injury and acute cerebrovascular 
accident (stroke) in Russia. MethOds: Short-term clinical and social outcomes 
(health status and disability rates) of rehabilitation were analyzed in the database 
of the Moscow Center of Speech Pathology and Neurological Rehabilitation. Changes 
in the officially registered disability rates and clinical outcomes were assessed for 3 
different strategies of rehabilitation: hospital, day care and home care. The decision 
tree model was constructed to simulate disability rates, direct and indirect costs of 
rehabilitation vs “no rehabilitation” scenario under conditions when officially regis-
tered disability corresponds to real health and functional status of patients. TreeAge 
Pro 2009 and Microsoft Excel 2010 software were used for modeling. Results: Use 
of officially registered disability as an endpoint does not reflect the actual effective-
ness of rehabilitation programs. 90% of patients are able to live without assistance 
after discharge but still are registered as 1stdegree disabled (most severe degree of 
disability in Russia) in order to receive social benefits. According to preliminary 
results of modeling total cost of rehabilitation may be less than cost of ”no reha-
bilitation” scenario if disability correlates with actual health and functional status 
of individuals, for example annual total cost is € 25,923 for home care rehabilita-
tion and € 28,124 for “no rehabilitation” scenario. cOnclusiOns: It’s necessary to 
improve approaches to official disability registration in Russia in order to make 
rehabilitation programs efficient.
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Objectives: We aimed at estimating and comparing the total management costs of 
patients admitted to the emergency department (ED) with recent (< 48 hours) atrial 
fibrillation (AF) between three types of cardioversion: direct current cardioversion 
(DCC), intravenous amiodarone or intravenous vernakalant. MethOds: A decision 
analytic model was developed to mimic the pathways of patients admitted via the 
ED with recent AF and to calculate an average AF management cost per strategy. 
The cardioversion success rates were based on published observational studies 
(DCC 90%, amiodarone 68%, vernakalant 70%). In case of successful conversion 
the patient was released directly from the ED to home (DCC 50%, amiodarone 25%, 
vernakalant 100%) or admitted to the hospital for a median of 1 day (DCC) or 2 
days (amiodarone) reflecting cardioversion-specific times to sinus rhythm. After 
a failed pharmacological cardioversion, patients were assumed to receive a DCC; 
failed DCC was followed by intravenous amiodarone. The associated inpatient costs 
were retrieved from the IMS Hospital Disease Database (HDD2011). ED treatments 
were costed using the national health care payer tariffs. Univariate and probabilistic 
sensitivity analyses were performed. Results: The total AF management costs 
from ED to discharge were estimated at € 952 (DCC), € 1,894 (amiodarone) and € 1.354 
(vernakalant). Given the relative frequencies of amiodarone (55%) and DCC (45%) to 
treat recent FA in Belgian ED, the weighted average management cost was € 1.470 
(+ € 116/treatment vs. vernakalant). The break-even situation is reached when 75% 
of successfully treated vernakalant patients avoid the hospitalization (base case 
100%). Based on a probabilistic sensitivity analysis, vernakalant was cost saving in 
55% of the 1,000 simulations vs. current management. cOnclusiOns: In patients 
with recent AF, the rapid mode of action of vernakalant increases the chance of 
obtaining sinus rhythm within 48 hours, and its use was cost saving compared to 
the current average Belgian practice.
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COst mOdEl analysis Of gORE® PROPatEn® VasCulaR gRaft VERsus 
standaRd EPtfE VasCulaR gRaft fOR infRaPOPlitEal byPass in 
PERiPhERal aRtERial disEasE (Pad) managEmEnt: sPanish sCEnaRiO
Scarpa F
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Objectives: Demonstrate the cost savings of using the GORE® PROPATEN® Vascular 
Graft compared to standard ePTFE vascular grafts in the management of PAD 
patients. Superior clinical outcomes in terms of primary / secondary patency and 
limb salvage rates result in lower average per-patient treatment costs. Background: 
Vascular bypass is used in patients with PAD (Peripheral Arterial Disease) to treat 
ischemic rest pain, to improve walking distance in patients with severe life-limiting 
claudication, and to save limbs that might otherwise require amputation. When 
patients presenting for peripheral artery reconstruction have absent or inadequate 
saphenous veins due to prior use, small size, or poor quality, vascular surgeons 
may choose a prosthetic bypass graft. The GORE® PROPATEN® Vascular Graft fea-
tures a proprietary end-point covalent linkage of heparin molecules to the luminal 
surface of the graft that provides sustained resistance to thrombosis. MethOds: 
A cost model analysis was developed to represent hospital treatment costs. A typical 
PAD patient’s treatment pathway in Spanish clinical practice was identified by a 
survey involving Spanish vascular surgeons. A literature review was conducted to 
determine patency and limb salvage rates. Spanish GRD AP27–2012-Ministerio de 
Sanidad tariffs were used as hospital cost of treatment inputs. A three-year patient 
management cycle was considered. Results: Better patency and limb salvage rates 
obtained using the GORE® PROPATEN® Vascular Graft result in fewer reinterven-
tions and amputations, corresponding to lower per-patient treatment costs. The 
cost model demonstrates an overall cost saving for PAD patient management using 
the GORE® PROPATEN® Vascular Graft for infrapopliteal bypass. The cumulative 
term effect of antihypertensive treatment on blood pressure was extracted from 
relative clinical trials and these data were extrapolated through the Hellenic SCORE 
and Framingham risk equations, estimating the long-term survival and quality-
adjusted life-years (QALYs) gained. Costs and outcomes were evaluated over life-
time, divided into annual cycles and were discounted at 3.0% with 2014 as reference 
year. The analysis was conducted from the Greek third-party-payer perspective 
(EOPYY). Results: The total lifetime cost related to V/A/H combination was esti-
mated to be lower (€ 10,970) compared to that of the O/A/H combination (€ 11,080), 
despite the higher drug acquisition cost. Moreover, the estimated QALYs gained with 
the V/A/H combination were 10.88 vs. 10.80 for O/A/H combination. Therefore, the 
V/A/H combination was found to be a dominant alternative over O/A/H combina-
tion, as it was associated with lower cost and greater efficacy. In a scenario when 
the ambulatory blood pressure measurements were taken into account, the ICER 
was far lower than the Greek GDP per capita (€ 6,845/QALY) vs. O/A/H combination, 
suggesting V/A/H combination to be a cost-effective choice. Extensive sensitiv-
ity analyses confirmed the robustness of the results. The probabilistic sensitivity 
analysis also demonstrated that there was about 80% probability for the V/A/H 
triple combination to be cost-effective at a willingness-to-pay threshold of € 16,000/
QALY. cOnclusiOns: This is the first study performed to compare the cost-utility 
of the two single-pill triple antihypertensive therapies. The V/A/H combination was 
proven dominant over the O/A/H combination for the treatment of moderate to 
severe hypertension.
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Objectives: To assess cost-effectiveness of high sensitivity troponin (hs-cTn) 
assays for the management of adults presenting with acute chest pain at the 
emergency department. MethOds: An economic model was constructed to esti-
mate lifetime costs and QALYs of five hs-cTn strategies (differing according to 
manufacturer, timing of the test, number of tests and cutoff point for a positive 
test result) compared to standard troponin (sTn) testing at presentation and at 
10-12 hours, which was considered the reference standard. In the base case, it 
was assumed that sTn testing had perfect accuracy for diagnosing AMI and only 
patients with a positive test for sTn were at increased risk for adverse events and 
would benefit from immediate treatment. In a secondary analysis, a proportion 
of patients with a positive hs-cTn test and a negative sTn test were at increased 
risk for adverse events and would benefit from immediate treatment. Results: 
Base case: Strategies considered cost-effective depending upon ICER thresholds 
were Abbott ARCHITECT hs-cTnI 99th centile (thresholds < £6,597), Beckman 
Coulter hs-cTnI 99th centile (thresholds £6,597 - £30,042), Abbott ARCHITECT hs-
cTnI optimal strategy (thresholds £30,042 - £103,194), and the sTn test (thresholds 
> £103,194). Secondary analysis: Strategies considered cost-effective were Abbott 
ARCHITECT hs-cTnI 99th centile (< £12,217), Roche Elecsys hs-cTnT 99th centile 
(£12,217 - £14,992) and Abbott ARCHITECT hs-cTnI optimal strategy (> £14,992). 
STn was dominated. Sensitivity/subgroup analyses: Main drivers are: the differ-
ence in outcomes between treated and untreated patients, and treatment costs 
for patients testing false-positive. Hs-cTn testing is more cost-effective in younger 
age, pre-existing coronary artery disease, and symptom onset < 3hrs ago. No test-
ing is only cost-effective when pre-test prevalence is 1%. cOnclusiOns: There 
is no strong evidence to prefer one hs-cTn testing strategy over another. Results 
do indicate that hs-cTn testing in general may be cost-effective compared to sTn 
testing, especially in the secondary analysis.
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Objectives: Recent studies have demonstrated the safety and efficacy of cath-
eter-based renal denervation (RDN) for the treatment of resistant hypertension. 
These studies have been used to estimate the cost effectiveness of this approach, 
however, there is no such published estimation in the Dutch health care setting. 
We aimed to determine the cost effectiveness of RDN from the perspective of 
the health care payer in The Netherlands. MethOds: A Markov state-transition 
model previously constructed in TreeAge® was adapted to Microsoft Excel®. The 
Excel-based model was updated with costs and quality-adjusted life years (QALYs) 
relevant to the Dutch setting and the cost effectiveness of RDN was compared 
with standard of care (SoC) for patients with resistant hypertension. The effi-
cacy of RDN treatment was modelled as a reduction in the risk of cardiovascular 
events associated with a lower systolic blood pressure (SBP). Results: Base case 
deterministic results showed that treatment with RDN resulted in an increase in 
QALYs of 0.89 at an incremental cost of € 1,315 per patient resulting in an ICER of 
just € 1,474 Deterministic and probabilistic sensitivity analyses (PSA) indicated 
treatment with RDN therapy was cost effective at conventional willingness-to-
pay thresholds used in The Netherlands of € 10,000–80,000 per QALY. Furthermore, 
9.5% of PSA iterations showed RDN to be a cost saving treatment compared to 
SoC. cOnclusiOns: RDN is a cost-effective intervention for patients with resist-
ant hypertension in The Netherlands.
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by LDL-C but treated to both LDL-C and LPL-P recommended goals. Results: In 
the general population, the costs per quality-adjusted life year (QALY) associated 
with the use of LDL-P alone were $76,052 at 5 years and $8,913 at 20 years and 
with the use of both markers were $142,825 at 5 years and $25,505 at 20 years. 
In high-risk subpopulations, the use of LDL-P alone was cost-saving at 5 years; 
whereas the cost per QALY for the use of both markers was $14,250 at 5 years and 
$859 at 20 years for high-risk dyslipidemics, $19,192 at 5 years and $649 at 20 years 
for diabetics, and $9,030 at 5 years and $7,268 at 20 years for patients with prior 
CHD. cOnclusiOns: Utilizing LDL-P to guide statin therapy is cost-effective in 
the long term for the general population, and cost-saving or cost-effective in the 
short term for high-risk patients.
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Objectives: The aim of this study was to evaluate the long-term cost effectiveness 
of ticagrelor + aspirin versus clopidogrel + aspirin in patients with acute coronary 
syndrome (ACS) treated for 12 months in Spain. MethOds: The cost effective-
ness model consisted of a decision tree (1st year) based on the PLATO study and 
a long-term Markov model (2nd year onwards). This allowed estimation of cardio-
vascular events (death, myocardial infarction and non-fatal stroke), survival, health 
costs, and health related quality of life. A life time horizon was applied. The daily 
drug cost was € 0.60 and € 2.96 for generic clopidogrel and ticagrelor, respectively. 
Spanish unit costs and life tables were used; outcomes and costs were discounted 
at 3%. A sensitivity analysis across subgroups was carried out, and probabilistic 
sensitivity analysis was used to validate the robustness of the model. Results: 
Ticagrelor compared to clopidogrel was associated with a gain of 0.1586 life years 
and 0.1363 years of quality-adjusted life years (QALY), with an incremental cost of € 
596. The incremental cost per life year and per QALY gained was € 3,760 and € 4,374, 
respectively. The probabilistic sensitivity analysis showed that ticagrelor was cost-
effective versus clopidogrel in > 99 % of the simulations given a willingness-to-pay 
threshold of € 15,000/QALY. The results were consistent across different subgroups 
of ACS patients. cOnclusiOns: Ticagrelor + aspirin for 12 months is a cost effective 
treatment compared to generic clopidogrel + aspirin in patients with ACS treated 
invasively or conservatively, based on the findings of the PLATO study and Spanish 
health care costs.
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Objectives: This study was conducted to determine the cost-effectiveness of 
carotid Artery stenting (CAS) versus carotid endarterectomy (CEA) in patients with 
symptomatic carotid stenosis (more than 50% stenosis) in Korean health care sys-
tem perspective. MethOds: We performed a cost-utility analysis. Costs were esti-
mated from retrospective chart review (CAS= 346, CEA= 331), health insurance claims 
data, and other national resources and expressed in 2013 KRW. Transition probabili-
ties were estimated from retrospective chart and systematic review. Health utility 
index was assessed for general population using Time Trade Off (TTO) with health 
scenario. We used a Markov model to project 15-year costs and quality-adjusted 
life years (QALYs) for the 2 treatment groups. Results: In the base case analysis, 
CAS produced 6.49 QALYs, compared with 6.71 QALYs for CEA. The incremental 
cost of stenting was 1,691,740 KRW. In the base case analysis, CEA for patients 
with symptomatic stenosis had a greater benefit than CAS, with lower costs. In 
subgroup for patients with stenosis more than 70% or patient with over 80 years 
old, CAS was cost-effective. Sensitivity analyses showed that the major stroke or 
mortality influenced the results. However the results were consistent with the base 
analysis. cOnclusiOns: Under the current circumstances in Korea, CEA was domi-
nated by CEA in symptomatic steonsis. Therefore we concluded that CEA would be 
cost-effective intervention for carotid stenosis. To be economically competitive, the 
clinical effectiveness such as mortality and major stroke rates of CAS must be at 
least equivalent if not less than those of CEA.
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Objectives: To estimate productivity loss and associated indirect costs in working-
age patients treated for hyperlipidemia. MethOds: A retrospective population-
based cohort study was conducted using Swedish electronic medical records 
linked to national health registers and the Social Insurance Register. Patients were 
included based on a prescription of lipid-lowering therapy between January 1,2006 
and December 31,2011 and followed until December 31,2012 for estimation of pro-
ductivity loss and cost outcomes. Patients were stratified into three cohorts based 
on cardiovascular (CV) risk level. Results: Total mean days lost, measured as the 
sum of net sick leave and net disability pension days, during the one-year period 
following study inclusion was highest in the CV event history cohort (n= 6,881; 159 
days), followed by the CV risk equivalent (RE) cohort (n= 3,226; 131 days) and the low/
cost savings at 3 years is estimated to be 11.671€ per patient. cOnclusiOns: The 
use of the GORE® PROPATEN® Vascular Graft for infrapopliteal bypass in the PAD 
patient population represents a safe, clinically effective, and cost-saving alternative 
to standard ePTFE vascular grafts.
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Objectives: Pharmacoeconomic analysis of rosuvastatin use in patients with 
hypercholesterolemia in the health care of Belarus has been performed to deter-
mine economic advisability of its applying in Belarus. As there is own production 
of statins (generics of lovastatin, atorvastatin and simvastatin) in Belarus, the 
insclusion of new statin (rosuvastatin) in the clinical protocols requires pharma-
coeconomic study. MethOds: Overview of statins available in Belarus has been 
conducted. Equivalent effective dose to achieve target of low density lipoprotein 
cholesterol (CH-LPLD) values were established on the basis of published data. Cost-
minimization analysis has been used. Model “decision tree” to achieve the target 
CH-LPLD values has been built on the basis of STELLAR trial. Statin doses required 
to achieve the target CH-LPLD values have been calculated. The costs of achieving 
the target CH-LPLD values have been evaluated. The cost of each statins treating 
during the year has been calculated. Results: The highest cost has been obtained 
for the equivalent dose of lovastatin ($ 0.35) compared with atorvastatin ($ 0.31) and 
simvastatin ($ 0.28) manufactured in Belarus. Average price rosuvastatin (Merten 
®) was comparable to the cost ($ 0.21) of Belarusian generics. The average cost of 
achieving the target CH-LPLD level was the lowest in the case of rosuvastatin - $ 170 
compared with atorvastatin ($ 200) and simvastatin ($ 286) considering available 
statins of all manufacturers. Due to rosuvastatin’s lower effective dosage the costs 
of the one-year treatment with rosuvastatin is lower (on average 94 $) than with 
atorvastatin (all manufacturers - $ 100) and simvastatin (202 $). cOnclusiOns: 
The study has demonstrated pharmacoeconomic acceptability of rosuvastatin use 
in the health care of Belarus.
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Objectives: To assess cost-effectiveness of indapamide 1.5 mg +amlodipine 5/10 
mg single-pill combination (SPC) compared with free combination (FC), in the 
Polish setting. MethOds: A Markov cohort simulation model was used. Results 
of meta-analysis by Gupta et al show a difference in patients’ compliance between 
SPC and FC. Better compliance results in lower systolic blood pressure, which 
influences risk of cardiovascular events. Hence, compliance is associated with 
life expectancy and quality of life. Cardiovascular disease risks were based on 
the Framingham risk equations. Life-time horizon, Polish public payer perspec-
tive and patient perspective were applied. Indapamide/amlodipine SPC cost is 
based on average pharmacy prices reported in April 2014 (18.13PLN and 19.75PLN 
respectively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was 
assumed. Cost of FC was calculated as an average cost of reimbursed indapamide 
and amlodipine products in corresponding doses. All costs present 2014 values, 
and are expressed in Polish zloty (PLN). Costs and effects were discounted with 
5% and 3.5% rates. Results: Indapamide/amlodipine SPC compared with FC gen-
erates additional life years (LYs) and quality adjusted life years (QALYs), and is 
highly cost-effective from public payer perspective and dominant from patient 
perspective. Difference between SPC and FC in LYs and QALYs was: 0.007960 and 
0.020809. Difference in total costs from public payer perspective and from patient 
perspective was 113.14PLN (27.07EUR) and -211.31PLN (-50.56 EUR). ICUR from 
public payer perspective was 5,437PLN/QALY (1,301EUR/QALY). At prices +199% vs 
the base-case, SPC remains a cost-effective technology from public payer perspec-
tive according to the legally defined CE threshold (111,381PLN/QALY= 26,653EUR/
QALY). At prices -9.9% vs base-case, SPC is a dominant/cost saving technology vs 
the FC comparator. cOnclusiOns: From public payer perspective, indapamide/
amlodipine SPC compared with FC is a highly cost-effective treatment option for 
hypertensive patients in contemporary Polish setting. From patient perspective, 
SPC is a dominant technology.
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Objectives: Numerous trials have shown that lowering LDL cholesterol (LDL-C) 
reduces CVD events; however, at any LDL-C level, residual risk remains. LDL parti-
cle concentration (LDL-P) may be a better predictor of events, but no studies have 
evaluated its cost-effectiveness. We used the Archimedes model to evaluate the 
cost-effectiveness of using LDL-C or LDL-P in preventing cardiovascular disease 
in dyslipidemic patients. MethOds: Archimedes is a highly detailed, large-scale 
simulation model of physiology, disease and health care systems. We created a 
simulated population of 1,000,000 individuals age 20-84 reflective of real subjects 
in the NHANES dataset. Because NHANES does not contain LDL-P values, they 
were imputed maintaining covariance with other biomarkers. The study had three 
arms: •Control: subjects evaluated for therapy for elevated LDL-C and treated 
with statins to LDL-C goals outlined in ATP-III; •LDL-P Alone: subjects evaluated 
and treated based solely on their LDL-P values; •Dual Arm: subjects evaluated 
